2018-19 Section 7-Neoplastic and Inflammatory Diseases of the Head and Neck eBook

Original Article

20. Taylor RJ, Chepeha JC, Teknos TN, et al. Development and valida- tion of the neck dissection impairment index: a quality of life mea- sure. Arch Otolaryngol Head Neck Surg. 2002;128:44-49. 21. Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL. A penetration-aspiration scale. Dysphagia. 1996;11:93-98. 22. Falchook AD, Green R, Knowles ME, et al. Comparison of patient- and practitioner-reported toxic effects associated with chemoradio- therapy for head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2016;142:517-523. 23. Strasser MD, Gleich LL, Miller MA, Saavedra HI, Gluckman JL. Management implications of evaluating the N2 and N3 neck after organ preservation therapy. Laryngoscope. 1999;109:1776-1780. 24. Setton J, Lee NY, Riaz N, et al. A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal can- cer treated with definitive intensity-modulated radiotherapy. Cancer. 2015;121:294-301. 25. Haughey BH, Hinni ML, Salassa JR, et al. Transoral laser microsur- gery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck. 2011;33:1683-1694. 26. Ringash J. Survivorship and quality of life in head and neck cancer. J Clin Oncol. 2015;33:3322-3327. 27. Nutting CM, Morden JP, Harrington KJ, et al; PARSPORT trial management group. Parotid-sparing intensity modulated versus con- ventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011; 12:127-136. 28. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated chemora- diotherapy aiming to reduce dysphagia in patients with oropharyn- geal cancer: clinical and functional results. J Clin Oncol. 2010;28: 2732-2738. 29. Vergeer MR, Doornaert PA, Rietveld DH, Leemans CR, Slotman BJ, Langendijk JA. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standard- ized follow-up program. Int J Radiat Oncol Biol Phys. 2009;74:1-8. 30. Klein J, Livergant J, Ringash J. Health related quality of life in head and neck cancer treated with radiation therapy with or without che- motherapy: a systematic review. Oral Oncol. 2014;50:254-262. 31. Peters LJ, Goepfert H, Ang KK, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 1993;26:3-11. 32. Wang K, Amdur RJ, Mendenhall WM, et al. Impact of post- chemoradiotherapy superselective/selective neck dissection on patient reported quality of life. Oral Oncol. 2016;58:21-26. 33. Holsinger FC, Ferris RL. Transoral endoscopic head and neck sur- gery and its role within the multidisciplinary treatment paradigm of oropharynx cancer: robotics, lasers, and clinical trials. J Clin Oncol. 2015;33:3285-3292. 34. Cancer Genome Atlas Network. Comprehensive genomic characteri- zation of head and neck squamous cell carcinomas. Nature. 2015; 517:576-582.

oropharyngeal cancer: first comparative results of patient-reported outcomes. Int J Radiat Oncol Biol Phys. 2016;95:1107-1114. 7. Beitler JJ, Chera BS. Protons for oropharyngeal cancer have not yet justified their promise. Int J Radiat Oncol Biol Phys. 2016;95: 1115-1116. 8. Chen AM, Felix C, Wang PC, et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol. 2017;18:803- 811. 9. Chera BS, Amdur RJ, Tepper J, et al. Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus- associated oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2015;93:976-985. 10. Marur S, Li S, Cmelak AJ, et al. E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuxi- mab in patients with HPV-associated resectable squamous cell carci- noma of the oropharynx-ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2017;35:490-497. 11. Yom SS, Gillison ML, Trotti AM. Dose de-escalation in human papillomavirus-associated oropharyngeal cancer: first tracks on pow- der. Int J Radiat Oncol Biol Phys. 2015;93:986-988. 12. Oncology N. NRG-HN002: a randomized phase II trial for patients with p16 positive, non-smoking associated, locoregionally advanced oropharyngeal cancer, NCT02254278. https://www.nrgoncology.org/ Clinical-Trials/Protocol-Table. Accessed March 14, 2018. 13. Robbins KT, Medina JE, Wolfe GT, Levine PA, Sessions RB, Pruet CW. Standardizing neck dissection terminology. Official report of the Academy’s Committee for Head and Neck Surgery and Oncol- ogy. Arch Otolaryngol Head Neck Surg. 1991;117:601-605. 14. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). https://ctep.cancer.gov/protocoldevelop- ment/electronic_applications/ctc.htm#ctc_40. Accessed March 14, 2018. 15. National Cancer Institute, Division of Cancer Control and Popula- tion Science. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). http:// appliedresearch.cancer.gov/pro-ctcae/. Accessed March 14, 2018. 16. Chera BS, Eisbruch A, Murphy BA, et al. Recommended patient- reported core set of symptoms to measure in head and neck cancer treatment trials. J Natl Cancer Inst. 2014;106(7). 17. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Orga- nization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376. 18. Bjordal K, Hammerlid E, Ahlner-Elmqvist M, et al. Quality of life in head and neck cancer patients: validation of the European Orga- nization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol. 1999;17:1008-1019. 19. Belafsky PC, Mouadeb DA, Rees CJ, et al. Validity and reliability of the Eating Assessment Tool (EAT-10). Ann Otol Rhinol Laryngol. 2008;117:919-924.

Cancer

June 1, 2018

106

Made with FlippingBook Annual report